Study of MG-K10 for prurigo nodularis
Part of Skin clinical trials.
This trial tests an investigational drug called MG-K10 for people with prurigo nodularis, a skin condition that causes intense itching and bumps. The goal is to see if it can help reduce itch and improve skin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with prurigo nodularis by a skin doctor for at least 3 months.
- Your worst itch over the past 24 hours is at least 7 out of 10, and your average weekly itch score is also at least 7.
- You have not used strong or very strong steroid creams or ointments on your skin within 2 weeks before starting the study.
- You do not have active tuberculosis or other skin conditions that could interfere with study results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an injection called SHR-1819 for adults with prurigo nodularis, a skin condition with itchy bumps. The goal is to see if it helps reduce itching and bumps.
This study looks at people with certain types of inflammatory skin conditions to improve how they are diagnosed and treated. It may help your care team by using a standardized approach, but you must be able to complete questionnaires and consent to participate.
This study tests whether the medication dupilumab can safely reduce itching and skin bumps in children aged 6 months to under 18 years who have prurigo nodularis, a skin condition that causes intense itching and nodules. Participation involves taking the study drug and tracking itch daily.
This study looks at how well nemolizumab works in real-world settings for adults with moderate-to-severe prurigo nodularis, a skin condition that causes intense itching and bumps. If you are starting this medication as part of your normal care, you may be able to join.
This trial tests an experimental drug called ICP-332 for people with prurigo nodularis (a condition causing very itchy, hard bumps on the skin). It aims to see if the drug can safely reduce itching and improve skin lesions.
This trial tests a new medication called MG-K10 for people with chronic spontaneous urticaria (chronic hives) that hasn't improved with standard antihistamines. The goal is to see if MG-K10 can reduce itching and hives.
Hear when a new Prurigo Nodularis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.